Alemtuzumab as treatment for MRD
ASO, allele-specific oligonucleotides; CMV, cytomegalovirus; Flow, flow cytometry; IV, intravenous; N, number; N/A, not available; PCR, polymerase chain reaction.
*Median 4 weeks;
**median 9 weeks;
†treatment study
Sign In or Create an Account